Cardiovascular benefits of PCSK9 inhibition [ 2011 - 2013 ]

Research Grant

Researchers: Prof Gilles Lambert (Principal investigator) ,  Prof Philip Barter (Principal investigator) ,  A/Pr Ranjit Thomas Grewal

Brief description PCSK9 is an inhibitor of the receptor that is responsible for removing LDL (the bad cholesterol) from the circulation. We will study the molecular mechanisms that inhibit PCSK9 at the protein level. This study is needed to understand if drugs that inhibit PCSK9 will diminish the risk of developing heart disease in patients who do not respond well to existing treatments, for example those who already had a cardiovascular event or those with familial hypercholesterolemia.

Funding Amount $AUD 518,386.38

Funding Scheme Project Grants

Notes Standard Project Grant